In the News: Pharma Data Protection Rules; Facial Recognition Restrictions; and UBS Fully Owns Its Chinese Operations

China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.

By Brian Chan and Krista Lee

China Releases Draft Rules on Data Protection in Pharmaceutical Trials

Chinese authorities have released draft measures to regulate the data protection period of pharmaceutical trials, including those from overseas.

Under the Implementing Measures for the Protection of Pharmaceutical Trial Data (Trial Implementation, Draft for Comments) (“Implementing Measures”) (药品试验数据保护实施办法（试行，征求意见稿）), (issued along with the Work Procedure for the Protection of Pharmaceutical Trial Data (Draft for Comments) (药品试验数据保护工作程序 (征求意见稿) ), the National Medical Products Administration (NMPA) proposes different data protection periods for three categories of drugs, according to an article by CMS Legal.

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English

✓ Newsletters with business-critical and sector-specific updates

✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now